Basic Information
| LncRNA/CircRNA Name | SNHG20 |
| Synonyms | SNHG20, C17orf86, LINC00338, NCRNA00338, SCARNA16HG |
| Region | GRCh38_17:77086716-77094990 |
| Ensemble | ENSG00000234912 |
| Refseq | NR_027058 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot etc. |
| Sample | lung tissues, cell lines (PC9, SPC-A1, NCIH1975, H1299, A549) |
| Expression Pattern | up-regulated |
| Function Description | SNHG20 was upregulated in non-small cell lung cancer (NSCLC) tissues compared with normal samples.Higher SNHG20 expression was significantly associated with advanced tumor, lymph node and metastases (TNM) stage and tumor size, as well as poorer overall survival.Moreover, knockdown of SNHG20 repressed NSCLC cell proliferation, migration and induced cell apoptosis.Mechanistic investigations revealed that SNHG20 could interact with EZH2(enhancer of zeste homolog 2),thereby repressing P21 expression. Furthermore, rescue experiments indicated that SNHG20 functioned as an oncogene partly via repressing p21 in NSCLC cells. Taken together, our findings demonstrate that SNHG20 is a new candidate for use in NSCLC diagnosis, prognosis and therapy. |
| Pubmed ID | 28981099 |
| Year | 2017 |
| Title | Long non-coding RNA SNHG20 promotes non-smallcell lung cancer cell proliferation and migration byepigenetically silencing of P21 expression |
External Links
| Links for SNHG20 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |